highly significantP ≤ .0006
Following perfusion of the CB1R-specific inverse agonist LY320135 , there was a marked reduction in normalised gamma power to 39.4 ± 10.1% of control, and this was highly significant ( P ≤ .0006, n = 9).
Following perfusion of the CB1R-specific inverse agonist LY320135 , there was a marked reduction in normalised gamma power to 39.4 ± 10.1% of control, and this was highly significant ( P ≤ .0006, n = 9).
When we next applied the inverse agonist LY320135 , we noted an increase in normalised beta power by 142.4 ± 88% of control, and this just failed to reach significance ( P ≤ .07, n = 9).